Clémenty J, Safar M, Vrancea F
Hôpital Cardiologique du Haut-Lévêque, Bordeaux Pessac.
Ann Cardiol Angeiol (Paris). 1989 Jan;38(1):47-51.
251 untreated patients with mild to moderate hypertension were included in a multicenter study aimed 1) to detect arrhythmias (24-H Holter recording) and 2) to assess the efficacy of sotalol on blood pressure and possible arrhythmias. Patients with coronary heart disease or previously documented arrhythmias were excluded. Atrial arrhythmias such as premature beats, fibrillation, flutter and paroxysmal atrial tachycardia were detected in 16% of patients. Monomorphic ventricular premature contractions (VPCs) (Lown I and II) were detected in 41% of patients and polymorphic VPCs or duplets/triplets (Lown III and IV) in 14%. A correlation seems to exist between the level of hypertensive cardiopathy, judged on electrocardiographic data (Tarazi classification), age of patients and severity of arrhythmias. Sotalol was administered during 2 months at a mean dose of 160 mg per day. The treatment was effective on blood pressure and arrhythmias (82% improvement of severe VPCs) and the drug was well tolerated. It was difficult to conclude if these good results are due to the betablocking properties or specific class II antiarrhythmic effects of sotalol or to the combined activity.
251例未经治疗的轻至中度高血压患者被纳入一项多中心研究,该研究旨在:1)检测心律失常(24小时动态心电图记录);2)评估索他洛尔对血压及可能出现的心律失常的疗效。冠心病患者或既往有记录的心律失常患者被排除。16%的患者检测到房性心律失常,如早搏、房颤、房扑和阵发性房性心动过速。41%的患者检测到单形性室性早搏(洛恩I级和II级),14%的患者检测到多形性室性早搏或成对/成三联律(洛恩III级和IV级)。根据心电图数据(塔拉齐分类)判断的高血压性心脏病程度、患者年龄与心律失常严重程度之间似乎存在相关性。索他洛尔给药2个月,平均剂量为每日160毫克。该治疗对血压和心律失常有效(重度室性早搏改善率达82%),且药物耐受性良好。很难确定这些良好结果是由于索他洛尔的β受体阻滞特性、特定的II类抗心律失常作用还是两者的联合作用。